MYCOF - NeuroPharm files provisional patent for Psilocybin in psychiatric disorders

Mydecine Innovations (MYCOF) wholly-owned subsidiary, NeuroPharm has filed a provisional patent application with the USPTO covering composition of matter claims regarding a psychedelic therapy enhancer for the treatment of certain psychiatric disorders, including PTSD.The patent application covers an enhancer that reduces the enzymatic breakdown of psilocin that causes psychedelic effects.The patent application covers methods that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects. This may result in an enhanced psychedelic experience in the treatment of PTSD, whether extended in time, intensity, intensity per dose, or a combination thereof."By reducing the enzymatic breakdown of psilocin, we may be able to enhance the therapeutic efficacy of psilocybin at lower dosages," commented Josh Bartch, CEO of Mydecine.Dose reduction may limit non-therapeutic impacts and lower the costs of administration.

For further details see:

NeuroPharm files provisional patent for Psilocybin in psychiatric disorders